Total Payments
$83,611
2024 Payments
$17,658
Companies
8
Transactions
67
Medicare Patients
5,704
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$43,969 (52.6%)
Consulting$36,396 (43.5%)
Travel$2,424 (2.9%)
Food & Beverage$823.05 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,969 | 24 | 52.6% |
| Consulting Fee | $36,396 | 17 | 43.5% |
| Travel and Lodging | $2,424 | 12 | 2.9% |
| Food and Beverage | $823.05 | 14 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $36,047 | 27 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $20,396 | 13 | $0 (2024) |
| Lilly USA, LLC | $17,618 | 14 | $0 (2024) |
| Eli Lilly and Company | $7,931 | 8 | $0 (2023) |
| Eisai Inc. | $1,402 | 2 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $105.28 | 1 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $71.00 | 1 | $0 (2023) |
| GE HEALTHCARE | $40.47 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,658 | 18 | Lilly USA, LLC ($17,509) |
| 2023 | $7,207 | 10 | Eli Lilly and Company ($5,681) |
| 2022 | $7,070 | 6 | Biogen, Inc. ($6,981) |
| 2021 | $19,320 | 14 | Biogen, Inc. ($14,570) |
| 2020 | $21,996 | 16 | Biogen, Inc. ($14,496) |
| 2019 | $750.00 | 1 | ACADIA Pharmaceuticals Inc ($750.00) |
| 2018 | $9,500 | 1 | ACADIA Pharmaceuticals Inc ($9,500) |
| 2017 | $109.00 | 1 | Lilly USA, LLC ($109.00) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Lilly USA, LLC | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $7,612.50 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Lilly USA, LLC | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $343.95 | General |
| 11/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $132.82 | General |
| 11/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $129.69 | General |
| 08/09/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,593.75 | General |
| Category: Neuroscience | ||||||
| 08/09/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Neuroscience | ||||||
| 08/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $283.57 | General |
| 08/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $203.25 | General |
| 08/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $194.25 | General |
| 08/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $139.67 | General |
| 08/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $132.82 | General |
| 07/31/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/19/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/12/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/29/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $40.47 | General |
| 04/09/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $51.71 | General |
| 02/27/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $43.01 | General |
| Category: Neuroscience | ||||||
| 12/13/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $71.00 | General |
| 10/25/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $105.28 | General |
| Category: PSYCHIATRY | ||||||
| 03/20/2023 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $55.58 | General |
| 03/20/2023 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $40.00 | General |
| 03/20/2023 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $36.92 | General |
| 03/07/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 03/01/2023 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,793 | 15,577 | $2.7M | $407,378 |
| 2022 | 19 | 1,334 | 11,556 | $1.8M | $268,206 |
| 2021 | 18 | 1,161 | 12,863 | $1.9M | $219,613 |
| 2020 | 21 | 1,416 | 13,189 | $2.6M | $262,017 |
Total Patients
5,704
Total Services
53,185
Medicare Billing
$1.2M
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | Office | 2023 | 70 | 70 | $228,820 | $153,729 | 67.2% |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | Office | 2023 | 59 | 59 | $413,295 | $68,481 | 16.6% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 346 | 363 | $664,218 | $37,483 | 5.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 279 | 315 | $131,138 | $37,340 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 185 | 185 | $133,485 | $28,470 | 21.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 92 | 92 | $49,788 | $21,142 | 42.5% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2023 | 288 | 299 | $443,183 | $13,169 | 3.0% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Office | 2023 | 66 | 66 | $15,959 | $12,559 | 78.7% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 66 | 72 | $219,888 | $11,616 | 5.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 40 | 47 | $12,806 | $4,016 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 52 | $16,016 | $3,876 | 24.2% |
| 70450 | Ct scan head or brain without contrast | Office | 2023 | 46 | 48 | $62,832 | $2,669 | 4.2% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2023 | 37 | 37 | $64,528 | $2,374 | 3.7% |
| 72157 | Mri scan of middle spinal canal before and after contrast | Office | 2023 | 13 | 13 | $44,421 | $2,236 | 5.0% |
| 70544 | Mri scan of blood vessels of head without contrast | Office | 2023 | 18 | 18 | $41,580 | $1,935 | 4.7% |
| 72146 | Mri scan of middle spinal canal without contrast | Office | 2023 | 26 | 26 | $50,232 | $1,652 | 3.3% |
| 70547 | Mri scan of blood vessels of neck without contrast | Office | 2023 | 13 | 13 | $31,659 | $1,644 | 5.2% |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | Office | 2023 | 86 | 13,790 | $27,580 | $1,530 | 5.5% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Office | 2023 | 12 | 12 | $40,884 | $1,456 | 3.6% |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | Office | 2022 | 56 | 56 | $356,608 | $67,603 | 19.0% |
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | Office | 2022 | 21 | 21 | $63,840 | $46,322 | 72.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 284 | 327 | $124,260 | $45,811 | 36.9% |
| 70551 | Mri scan of brain without contrast | Office | 2022 | 257 | 267 | $442,152 | $28,775 | 6.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 118 | 118 | $75,420 | $19,985 | 26.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 57 | 57 | $50,445 | $16,338 | 32.4% |
About Dr. Dylan Wint, MD
Dr. Dylan Wint, MD is a Neurology healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922057116.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dylan Wint, MD has received a total of $83,611 in payments from pharmaceutical and medical device companies, with $17,658 received in 2024. These payments were reported across 67 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($43,969).
As a Medicare-enrolled provider, Wint has provided services to 5,704 Medicare beneficiaries, totaling 53,185 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Psychiatry
- Location Las Vegas, NV
- Active Since 05/08/2006
- Last Updated 05/17/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1922057116
Products in Payments
- NUPLAZID (Drug) $19,146
- KISUNLA (Drug) $15,906
- ADUHELM (Biological) $14,206
- AMYVID (Drug) $152.01
- REXULTI (Drug) $105.28
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Las Vegas
Mr. Zoltan Mari, Md, MD
Neurology — Payments: $557,878
Neurology $557,878
Le Hua, M.d, M.D
Neurology — Payments: $527,646
Neurology $527,646
Dr. Abraham Nagy, M.d, M.D
Neurology — Payments: $314,938
Neurology $314,938
Dr. Carrie Hersh, D.o, D.O
Neurology — Payments: $311,872
Neurology $311,872
Dr. Fan Zhang, Do, DO
Neurology — Payments: $257,387
Neurology $257,387
Dr. Nicole Theuvenet, M.d, M.D
Neurology — Payments: $220,553
Neurology $220,553